» Articles » PMID: 38454301

Avoidant/restrictive Food Intake Disorder Prevalence is High in Children with Gastroparesis and Functional Dyspepsia

Overview
Date 2024 Mar 8
PMID 38454301
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Avoidant/restrictive food intake disorder (ARFID) prevalence in children with gastroparesis (Gp) and/or functional dyspepsia (FD) is unknown. We aimed to identify ARFID prevalence and trajectory over 2 months in children with Gp, FD, and healthy children (HC) using two screening questionnaires. We also explored the frequency of a positive ARFID screen between those with/without delayed gastric emptying or abnormal fundic accommodation.

Methods: In this prospective longitudinal study conducted at an urban tertiary care hospital, patients ages 10-17 years with Gp or FD and age- and gender-matched HC completed two validated ARFID screening tools at baseline and 2-month follow-up: the Nine Item ARFID Screen (NIAS) and the Pica, ARFID, and Rumination Disorder Interview-ARFID Questionnaire (PARDI-AR-Q). Gastric retention and fundic accommodation (for Gp and FD) were determined from gastric emptying scintigraphy.

Key Results: At baseline, the proportion of children screening positive for ARFID on the NIAS versus PARDI-AR-Q was Gp: 48.5% versus 63.6%, FD: 66.7% versus 65.2%, HC: 15.3% versus 9.7%, respectively; p < 0.0001 across groups. Of children who screened positive at baseline and participated in the follow-up, 71.9% and 53.3% were positive 2 months later (NIAS versus PARDI-AR-Q, respectively). A positive ARFID screen in Gp or FD was not related to the presence/absence of delayed gastric retention or abnormal fundic accommodation.

Conclusions & Inferences: ARFID detected from screening questionnaires is highly prevalent among children with Gp and FD and persists for at least 2 months in a substantial proportion of children. Children with these disorders should be screened for ARFID.

Citing Articles

Assessing Avoidant/Restrictive Food Intake Disorder (ARFID) Symptoms Using the Nine Item ARFID Screen in >9000 Swedish Adults With and Without Eating Disorders.

Presseller E, Cooper G, Thornton L, Birgegard A, Abbaspour A, Bulik C Int J Eat Disord. 2024; 57(11):2143-2155.

PMID: 39115175 PMC: 11560655. DOI: 10.1002/eat.24274.

References
1.
Schol J, Wauters L, Dickman R, Drug V, Mulak A, Serra J . United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. United European Gastroenterol J. 2022; 9(7):883-884. PMC: 9073716. DOI: 10.1002/ueg2.12090. View

2.
Febo-Rodriguez L, Chumpitazi B, Sher A, Shulman R . Gastric accommodation: Physiology, diagnostic modalities, clinical relevance, and therapies. Neurogastroenterol Motil. 2021; 33(12):e14213. DOI: 10.1111/nmo.14213. View

3.
Bryant-Waugh R, Stern C, Dreier M, Micali N, Cooke L, Kuhnle M . Preliminary validation of the pica, ARFID and rumination disorder interview ARFID questionnaire (PARDI-AR-Q). J Eat Disord. 2022; 10(1):179. PMC: 9682666. DOI: 10.1186/s40337-022-00706-7. View

4.
Atkins M, Zar-Kessler C, Madva E, Staller K, Eddy K, Thomas J . History of trying exclusion diets and association with avoidant/restrictive food intake disorder in neurogastroenterology patients: A retrospective chart review. Neurogastroenterol Motil. 2023; 35(3):e14513. PMC: 11262773. DOI: 10.1111/nmo.14513. View

5.
Eseonu D, Su T, Lee K, Chumpitazi B, Shulman R, Hernaez R . Dietary Interventions for Gastroparesis: A Systematic Review. Adv Nutr. 2022; 13(5):1715-1724. PMC: 9526854. DOI: 10.1093/advances/nmac037. View